Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03680508
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:04.296548+00:00
Published At
2026-04-02T00:00:00+00:00
Record Updated At
2026-04-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Primary Liver Cancer", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-02"
protocolSection.identificationModule.nctId
"NCT03680508"
protocolSection.identificationModule.officialTitle
"Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Adult Primary Liver Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Adult Primary Liver Cancer (protocolSection.conditionsModule.conditions)
  • Localized Unresectable Adult Primary Liver Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.